West Tower Group’s Acadia Pharmaceuticals ACAD Stock Holding History

West Tower Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-97	Closed	-$2.02K	–	492
2023 Q3	$2.02K	Buy	+97	New	+$2.63K	﹤0.01%	572

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

West Tower Group's ACAD Position: Q4 2023 in Review

West Tower Group sold out of Acadia Pharmaceuticals (ACAD) in Q4 2023, closing a stake of 97 shares — an estimated $2.02K sold.

West Tower Group first reported a position in ACAD in Q3 2023 and held it in 1 quarter. The position peaked at $2.02K in Q3 2023. 276 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.

West Tower Group reported no remaining Acadia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
West Tower Group sold 97 Acadia Pharmaceuticals shares in Q4 2023, an estimated $2.02K.
West Tower Group first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 1 quarter.
West Tower Group's Acadia Pharmaceuticals position peaked at $2.02K in Q3 2023.
276 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.

Based on West Tower Group's 13F filing for Q4 2023, filed 14 Feb 2024.